High-dose therapy with autologous blood progenitor cell support is now routinely used for patients with certain malignant lymphomas and multiple myeloma. We performed a prospective cost analysis of the mobilization, harvesting and cryopreservation phases and the high-dose therapy with stem cell reinfusion and hospitalization phases. In total, 40 consecutive patients were studied at four different university hospitals between 1999 and 2001. Data on direct costs were obtained on a daily basis. Data on indirect costs were allocated to the specific patient based on estimates of relevant department costs (ie the service department's costs), and by means of predefined allocation keys. All cost data were calculated at 2001 prices. The mean total costs for the two phases were US$ 32 160 (range US$ 19 092-50 550). The mean total length of hospital stay for two phases was 31 days (range 27-37). A large part of the actual cost in the harvest phase was attributed to stem cell mobilization, including growth factors, harvesting and cryopreservation. In the high-dose chemotherapy phase, the most significant part of the costs was nursing staff. Average total costs were considerably higher than actual DRG-based reimbursement from the government, indicating that the treatment of these patients was heavily subsidized by the basic hospital grants.
Summary:
High-dose therapy with autologous blood progenitor cell support is now routinely used for patients with certain malignant lymphomas and multiple myeloma. We performed a prospective cost analysis of the mobilization, harvesting and cryopreservation phases and the high-dose therapy with stem cell reinfusion and hospitalization phases. In total, 40 consecutive patients were studied at four different university hospitals between 1999 and 2001. Data on direct costs were obtained on a daily basis. Data on indirect costs were allocated to the specific patient based on estimates of relevant department costs (ie the service department's costs), and by means of predefined allocation keys. All cost data were calculated at 2001 prices. The mean total costs for the two phases were US$ 32 160 (range US$ 19 092-50 550). The mean total length of hospital stay for two phases was 31 days (range 27-37). A large part of the actual cost in the harvest phase was attributed to stem cell mobilization, including growth factors, harvesting and cryopreservation. In the high-dose chemotherapy phase, the most significant part of the costs was nursing staff. Average total costs were considerably higher than actual DRG-based reimbursement from the government, indicating that the treatment of these patients was heavily subsidized by the basic hospital grants. Bone Marrow Transplantation (2005) 35, 1149-1153. doi:10.1038/sj.bmt.1704988 Published online 9 May 2005 Keywords: myeloma and lymphoma; high-dose chemotherapy; peripheral blood stem cell; cost analysis High-dose chemotherapy (HDT) with autologous peripheral blood stem cell (PBSC) support is now an established treatment strategy for poor-prognosis malignancies, such as certain categories of malignant lymphoma and multiple myeloma. [1] [2] [3] [4] Faster recovery of the peripheral blood cell count, decreased procedure-related morbidity, mortality and shorter hospital stay compared to use of marrow stem cells have led to the widespread use of HDC with PBSC support. 5, 6 Autologous PBSC replaced bone marrow at the Norwegian Radium Hospital (NRH) in 1993 for malignant lymphoma. The Rikshospitalet University Hospital performed the first peripheral blood stem cell transplant (PBSCT) in a patient with acute myeloid leukemia in 1990. From 1990, PBSC gradually replaced bone marrow as the stem cell source. An investigational trial in the Nordic countries for myeloma was started in 1995. The main results were published in 2000. 7 At present, 50-60 patients with myeloma and 60-70 patients with lymphoma undergo HDT with PBSC at Norwegian centers each year.
In 1997, the Norwegian central government introduced prospective payment of inpatients based on a Nordic version of the Diagnosis Related Group (DRG) system. HDT was not included in this reimbursement system as a special procedure although it has been regarded as standard treatment for malignant lymphoma since 1995. Instead, the relevant patients were divided into groups of DRG (DRG 403 lymphoma and nonacute leukemia with complication and DRG 404 lymphoma and nonacute leukemia without complication) that did not take into account the special costs related to the procedure. Costs not reflected in the DRG-reimbursement were assumed to be covered by the hospitals' basic grants. As a consequence of this reimbursement system and since the basic grants are set on rather pragmatic grounds and are assumed to cover a broad and not clearly defined set of tasks, we decided to undertake a prospective analysis of the costs of HDT for patients with multiple myeloma and malignant lymphoma at four university hospitals. We analyzed the costs of mobilization, harvesting and cryopreservation, and the HDT phase.
Patients and treatment
Between May 2001 and December 2001, 20 consecutive patients with early multiple myeloma admitted to the hematological departments at the Ulleva˚l University Hospital and Haukeland University Hospital, and 10 lymphoma patients at the NRH were included in the prospective analysis. In total, 10 patients from Rikshospitalet University Hospital with multiple myeloma were studied from 1999 to 2000. Before being considered for HDT, myeloma patients were required to have responded to, or not to have disease progression following, 3-4 VAD (vincristine, adriamycin, dexamethasone) courses. Patients with malignant lymphoma all had chemosensitive disease with at least a partial response (PR) to MIME (methyl-GAG, ifosfamide, methotrexate, etoposide) or ICE (ifosfamide, carboplatine, etoposide). They were in relatively good general condition, without severe heart, lung or renal disease or uncontrolled infection. See Table 1 for patient characteristics. Costs were calculated for the following phases:
1. Mobilization, harvesting and cryopreservation for myeloma patients, using cyclophosphamide 2 g/m 2 body surface followed by G-CSF. For malignant lymphoma patients MIME (methyl-GAG, ifosfamide, methotrexate, etoposide) ICE (ifosfamide, carboplatine, etoposide) were used, the latter supported by G-CSF. 2. HDT with infusion of autologous stem cells was followed by hospitalization. Myeloma patients received melphalan 200 mg/m 2 and lymphoma patients BEAM (carmustine, etopside, cytarabine, melphalan).
Medical history, clinical, laboratory and outcome data were obtained from the medical records.
Stem cell mobilization, harvesting and cryopreservation
Stem cells were mobilized with chemotherapy as mentioned in the previous section followed by G-CSF, 5 mg/kg/b.i.d. PBSC collection was performed by large volume leucapheresis, usually at 10 or 11 days after the chemotherapy. In some of the lymphoma patients, CD34 þ cells were isolated using the Baxter Isolex 300 system. Harvested cells were cryopreserved according to GMP procedures, using DMSO as cryoprotectant.
Supportive care and hospitalization
During the mobilization phase, patients were usually hospitalized for 4-5 days for evaluation, insertion of a central venous catheter and chemotherapy. They were then discharged until stem cell collection, usually for 1-3 days.
HDT, transfusion of stem cells and the aplasia period were usually spent as an inpatient. Patients were treated in conventional single rooms and usually hospitalized for 2-3 weeks. Side effects such as nausea, vomiting, mucositis, neutropenic fever and cytopenia were treated according to standard procedures. Erythrocyte transfusions were given if the hemaglobin fell below 8 g/dl and thrombocytes when the platelet count fell below 10 Â 10 9 /l. Hospitalization was partly necessary because most patients lived far from the university hospitals, but also because of lack of appropriate outpatient hotel facilities at the time of this study. Some patients needed hospital care because they were debilitated by conditions related to their disease, such as skeletal problems, or due to side effects such as reaction to the HDT (BEAM) in the case of the lymphoma patients. Table 2 presents descriptive statistics for length of stay for the two phases.
Cost analysis
The cost method involved two sets of data: a data set including patient-related or direct costs, and a data set including nonpatient-related or indirect costs. The basic principle of the study was that the costs should be recorded at the individual patient level. 8 A prospective registration method was applied to collect direct patient related data during hospitalization. These data were divided into the following cost items: (1) hospitalization and basic medical service, including medical and nursing staff; (2) pharmacy and blood products; (3) procedures such as operating theatre, leucapheresis and cryopreservation.
Indirect costs were estimated from the clinical service department costs, for instance, radiology, clinical chemistry, pharmacy and the nonclinical service departments such as transportation, housekeeping-and kitchen services. Allocation of indirect costs was performed through a set of predefined allocation keys, such as the number of patients discharged and length of stay. Capital costs were not included. To obtain cost per discharged patient, the Autologous peripheral blood stem cell transplantation V Mishra et al clinical department's operating costs were divided by the total number of discharged patients corrected for patient mix for that unit in a given year. Costs related to treatment in other hospitals and at outpatient clinics were not included in the analysis.
Results
All cost data are reported at 2001 prices and have been recalculated into US$ by using the exchange rates of 1st January 2001. Table 3 shows a mean cost for the mobilization/cryopreservation phase per patient of US$ 6544 (range 5114-7273). The mean cost of HDT followed by hospitalization was US$ 25 616 (13 978-43 277). This amounts to total running costs of US$ 32 160 (19 092-50 550). The significant cost variation between different hospitals was further examined. The major contributing factors to total costs were personnel costs, medication and blood products. There were significant differences in the use of all these three factors between the different hospitals ( Figure 1 ).
Taken together, staffing, medication and blood products contributed to 74% of total costs. On average, 53% of total costs comprised staff costs, ranging from 39 to 76%. Personnel resources varied from one center to another, from US$ 12 608 to US$ 26 038 per patient. Pharmacy and blood products contributed 16 and 5%, respectively, of the total costs.
Differences in blood product expenses at patient level are further described in Figure 2 . The figure indicates a considerable variation, with mean cost variations from US$ 709 to US$ 6304. Hospital C and D reported a higher use of blood products than the other centers. Two patients at hospitals C and D should be regarded as 'outliers' with a cost of blood products of US$ 15 000 and US$ 12 100.
Discussion
The study describes all running costs associated with health care provided to patients undergoing mobilization, harvesting and cryopreservation of stem cells followed by HDT with stem cell rescue, at four university hospitals. An important feature of this study is the prospective collection of cost data. The cost items for each patient were determined daily, to enable analysis of different cost items during hospitalization. Several cost analysis studies of HDC with PBSC support have been published. 9-11 Different financing and accounting systems and calculation methods make it difficult to compare costs from different centers within countries and between countries. However, some comparisons are possible.
A study by Van Agthoven 12 documented total costs of PBSC transplantation at Euro 33 742. The author applied a unit cost method where staff costs accounted for 42% of the transplant cost, as compared to our study where they accounted for 53% of the total running costs. This relatively large difference in staff costs is notable, and may indicate there are cost variations between different countries, for example, related to wages. The author reported a remarkably low cost per patient for the stem cell harvesting and cryopreservation procedures, an average of EUR 4982, and a blood component cost (during the induction chemotherapy regimen, harvesting and transplantation phase), respectively, of EUR 904, EUR 376 and EUR 1680, a total of EUR 2960.
In a recent study, Ghosh et al 13 reported a PBSCT cost for patients with plasma cell leukemia that ranged from US$ 20 000 to US$ 25 000. The major part of the costs related to hospitalization, growth factors, blood products, collection and cryopreservation of PBSC. A comparison with our study is difficult due to different cost analysis methods and distribution of overhead costs and possibly to other patient factors. Figure 2 Blood product cost at individual patient level.
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Cost differences between hospitals are significant in our study and deserve some comment. We cannot rule out the possibility that some of the differences are related to methodological matters, including differences in accounting systems between hospitals as well as the limited availability of cost data in some hospitals. 9 However, the study was based on a common methodology where staff members taking part in the study were trained in the use of the database related to direct cost registration before the study started. Also, indirect costs should be calculated in a similar way. However, the differences in the quantity of pharmacy and blood products used were so high that we suspect that some of the institutions may have failed to register these data accurately prospectively, or that these differences may be attributed to some other organizational reasons of which we may not be fully aware. There may also be some variations in the level of detail to which each hospital has been able to collect financial information on some items. The small number of patients in this study may also affect our results.
However, the differences in costs between hospitals may also be explained by some structural factors.
1. The four centers have different functions. For instance, hospitals A and B both have local and regional hospital functions. Hospital C is a comprehensive cancer center with regional, and some national, functions. At hospital D, 80% of activity is related to regional and national functions relating to major and costly specialities and procedures, it being the only center of transplantation activity in Norway. Regional and national function patients are generally more resource demanding, needing highly specialized and often high-risk, expensive treatments, and therefore more personnel per patient are needed. 2. Case-mix: during the study period, the general case-mix index for hospital A was 1.05, and for hospital B 1.04. The case-mix index for hospital C was not available. For hospital D it was 1.20. This indicates that hospital D, a national referral hospital, had patients that on average needed approximately 15% more resources than the two other hospitals. Hospital D treats patients who are more resource-demanding, receiving one-to-one care, expensive drugs and chemotherapy and undergoing high cost procedures, which results in a very high case-mix index. 3. Overhead costs: differences in overhead costs are mainly due to variations in organizational form, staffing and infrastructure costs. Hospitals A, B and D are major university hospitals, each with a total staff of more than 4000. The analysis shows that, due to these differences, there were on average 15% higher overhead costs per patient at hospitals A, B and D than in C, which is a comprehensive cancer center with a staff of 1800. Mean hospital administration and maintenance costs were almost 11% higher per patient at hospital D compared to A and B. 4. Major cost variables: overall staff costs, pharmacy costs and blood product costs. The study showed significant variations for all these elements, which may be due to differences in medical practice and differences in preferences for, and pricing of, pharmaceutical products. It is well known that individual patients may use large quantities of blood products and/or expensive drugs, which may partially explain this observation. Nevertheless, it is of note that no patients in hospital A and B used blood products costing more than US$ 2000. These differences are notable since there is consensus on the indication for transfusion, and the price of blood products is the same at all hospitals. However, the variation is also probably due to factors such as (1) the fact that lymphoma patients were treated at a later phase of their diseases, (2) and have therefore received more chemotherapy and (3) that BEAM gives rise to a longer period of aplasia than does melphalan in myeloma.
Length of stay (LOS). Several studies have investigated,
by standard regression techniques, the influence of various patient demographic variables, clinical factors and treatment on LOS and hospital cost. [14] [15] [16] [17] Our study result shows that LOS for the two phases varied from 27 to 37 days ( Table 2 ). The differences between hospital LOS may in part be due to geographic factors. Some patients live relatively close to their hospital and may be discharged and rehospitalized for treatment during the aplasia period. Patients living far from their hospital must stay in hospital for safety reasons.
Finally, some more general limitations to this study must be noted. Firstly, we collected only hospitalization cost data from the hospitals' perspectives. Cost related to the use of a patient hotel for some part of the stay is not included. Patient hotel stays have become common practice is Norway, where distance to the patient's home often makes travel difficult. It is also common in other countries in Western Europe and in the United States. 18 Secondly, costs were calculated only for hospitalization, and costs related to outpatient clinic visits at the study hospitals and at other hospitals were not included in our analysis, probably resulting in an underestimation of the total costs for the treatment program. Thirdly, costs related to academic and research functions were not calculated.
A final remark relates to the financing of the kind of procedures analyzed here. While nearly all in-patients and day surgical patients are included in and financed through the DRG-system in Norway, no DRG was established for HDT treatment of myeloma and non-Hodgkin's lymphoma (see Table 3 ). The data presented in this study may be helpful to the health authorities to establish a DRG reimbursement for HDT treatment of myeloma and nonHodgkin's lymphoma in Norway.
In conclusion, even though the costs related to advanced medical treatment such as those described here are likely to change in the future, important information has been gained from our study. The prospective cost analysis approach provides a valuable starting point in understanding the cost and improving the financial efficiency of providing modern care to myeloma and lymphoma patients. assistance in providing cost data for leucapheresis, harvest, cryopreservation and blood products.
